Transient Eruptive Keratoacanthomas Associated with Nivolumab: A Case Report
DOI:
https://doi.org/10.21276/apalm.3602Keywords:
Immune checkpoint inhibitors, Eruptive Keratoacanthoma, Cutaneous adverse effect, NivolumabAbstract
Immune checkpoint inhibitors are increasingly being utilized for the treatment of advanced neoplastic disease and have been associated with cutaneous adverse effects. We are reporting a case of eruptive keratoacanthomas in a patient 24 months after initiation of nivolumab for cHL. Treatment with topical ultra-high potency corticosteroid and third generation retinoid stopped the development of new lesions and healed previous lesions. 5-FU, imiquimod, cryotherapy, and curettage are other methods to treat. Most of these were treated with topical and intralesional corticosteroids, excision, or cryotherapy. Eruptive keratoacanthoma is a rare adverse effect of immune checkpoint inhibitors. Oncologists and dermatologists must be aware of this cutaneous adverse effect as their use has been increased. Appropriate treatment can control and manage the lesions.
References
1. Antonov N, Nair K, Halasz C. Transient eruptive keratoacanthomas associated with nivolumab. JAAD Case Rep. 2019;5(4):342-5.
2. Karampinis E, Kostopoulou C, Toli O, Marinos L, et al. Multiple Keratoacanthoma-like Syndromes: Case Report and Literature Review. Medicina (Kaunas). 2024;60(3):371.
3. Bednarek R. Marks K, Lin G, et al. Eruptive Keratoacanthomas secondary to nivolumab immunotherapy. Int J Dermatol. 2018 57(3):e28-e29.
4. Eric O, Steven S, Montanez-Wiscovich M, et al. Multiple Eruptive Keratoacanthomas Secondary to Nivolumab Immunotherapy. J Immunother. 2024;47(3):98-100.
5. Karampinis E, Kostopoulou C, Toli O, et al. Multiple Keratoacanthoma-like Syndromes: Case Report and Literature Review, Medicina (Kaunas). 2024;60(3):371.
6. Poole M, Schwartz R, Lambert W. et al. To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma. Arch Dermatol Res. 2022:315(7).
7. Sullivan D, Sakamoto G. Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma. Cutis. 2023;111(5):E13-E15.
8. Crow L, Perkins I, Twigg A, et al. Treatment of PD-1/PD-L1 Inhibitor-Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas. JAMA Dermatol. 2020;156(5):598-600.
9. Shi V, Rodic N, Gettinger S, et al. Clinical and Histological Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatol. 2016;152(10):1128-36.
10. Sibaud V. Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254-63.
11. Bhardwaj M. Nee Chiu M, Sah S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022;41(1):73-90.
12. Ellis S, Vierra A, Millsop J, et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. J Am Acad Dermatol. 2020;83(4):1130-43.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Trupti Dongre, Mahesh Deshmukh, Amol Dongre , Sushil Pande
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
